Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GCSF in Post Kasai Type 3 Biliary Atresia
NCT06708572Recruiting
- Sponsor
- National Liver Institute
- Start
- Dec 2024
- Primary completion
- Oct 2026
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Open-label trial of granulocyte colony-stimulating factor in biliary atresia (2 arms), sponsored by National Liver Institute. Primary endpoint: Proportion of subjects with serum Total Bilirubin >= 2 mg/dL at 3 months. Started Dec 2024; status: recruiting.
02
Drugs
granulocyte colony-stimulating factor
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NCT06708572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06708572.